Aperçu du dossier

In a significant victory for Apple Inc., the United States District Court for the District of Delaware entered final judgment on February 11, 2026, invalidating a core panoramic lens patent asserted against the iPhone 13 Pro and iPhone 13 Pro Max. The court found Claim 21 of U.S. Patent No. 6,844,990 invalid for lack of enablement — a decisive ruling that ends over four years of litigation initiated by ImmerVision, Inc., a Montreal-based optical technology company.

The case, docketed as 1:21-cv-01484, carries meaningful implications for wide-angle imaging patent litigation, camera technology IP strategy, and the growing body of enablement doctrine jurisprudence in district courts. For patent attorneys, in-house IP counsel, and R&D teams working in computational photography or optical systems, this outcome offers critical lessons about patent drafting, claim scope, and litigation risk when asserting aging technology patents against modern consumer electronics.

Les parties

Le brevet en cause

The asserted patent, U.S. Patent No. 6,844,990 B2 (application no. US10/706,513), covers optical lens technology in the wide-angle and panoramic imaging domain. Claim 21, the specific claim at issue, was the focal point of ImmerVision’s infringement allegations. Patents in this era of optical technology often contain broad functional claims that face heightened scrutiny when asserted against significantly more advanced successor technologies.

• • US 6,844,990 — Wide-angle and panoramic optical lens technology (Claim 21)

Le verdict et l'analyse juridique

Résultat

The court entered judgment in favor of Defendant Apple Inc. and against Plaintiff ImmerVision, Inc. on all matters before it. Specifically, the court adjudged Claim 21 of U.S. Patent No. 6,844,990 invalid for lack of enablement under 35 U.S.C. § 112. No damages were awarded. This outcome is notable because it bypasses infringement analysis entirely: if a claim is invalid, no infringement can be found regardless of product similarity.

Verdict Cause Analysis: Lack of Enablement

The enablement doctrine under 35 U.S.C. § 112(a) requires that a patent specification enable a person of ordinary skill in the art (POSITA) to make and use the full scope of the claimed invention without undue experimentation. When a patent claim is written broadly — particularly functional claims covering a wide range of implementations — courts scrutinize whether the specification actually teaches practitioners how to practice the entire claimed scope.

The Supreme Court’s 2023 decision in Amgen Inc. v. Sanofi reinvigorated enablement challenges against functionally broad patent claims, establishing that patentees cannot “claim a lot and enable a little.” While the specific reasoning in D.I. 267 was not reproduced in the available data, the invalidation of Claim 21 on enablement grounds strongly suggests the court found a disconnect between the breadth of ImmerVision’s claim language and what the specification actually disclosed — a pattern frequently observed when older optical patents are asserted against modern imaging implementations.

Signification juridique

This ruling contributes to the developing body of post-Amgen enablement jurisprudence at the district court level, particularly as applied to optical and imaging technology patents. It signals that Delaware courts will rigorously apply enablement requirements to functionally drafted claims in hardware-adjacent technology domains — not merely in the life sciences context where Amgen originated. For patent litigators, the case reinforces that invalidity under § 112 is a viable and potentially case-dispositive defense, particularly when the asserted patent predates the accused technology by a significant technological generation.